GRI Bio, Inc. (GRI)
Develops medicines targeting immune cells to treat lung fibrosis and autoimmune diseases.
$1.43+0.01%Healthcare
StockGlow Score
Bearish
BearishBullish
1 year ago-96.1%
The outlook
GRI is trading near its 52-week low with a StockGlow score of 19/100, indicating bearish sentiment overall. The stock sits below both its 50- and 200-day moving averages, suggesting weak near-term momentum. Notably, analyst price targets average around $20.98, roughly 13x the current price, though such wide gaps often reflect thin or speculative coverage.
What’s behind the score
Price trendBelow its 50- & 200-day averages
52-week range0% of the way from its 52-week low to high
Price targetAvg target +1369% vs current price
Analyst price target
~12-month · 2 analysts$21.00average target+1368.5% vs now
Now $1.43
Low $10.00High $32.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$2.5M
52-wk high
$80.36
52-wk low
$1.39
50-day avg
$1.91
200-day avg
$14.39
Trailing P/E
0.0